Silencing mitogen-activated protein kinase-activated protein kinase-2 arrests inflammatory bone loss. - Wikidata - awgldk - TriplyDB

Silencing mitogen-activated protein kinase-activated protein kinase-2 arrests inflammatory bone loss.

Silencing mitogen-activated protein kinase-activated protein kinase-2 arrests inflammatory bone loss.

http://www.wikidata.org/entity/Q34702307

about

Differential expression of mitogen activating protein kinases in periodontitis.Sexual Dimorphism in MAPK-Activated Protein Kinase-2 (MK2) Regulation of RANKL-Induced Osteoclastogenesis in Osteoclast Progenitor Subpopulations.MAPK usage in periodontal disease progression.Oral inflammatory diseases and systemic inflammation: role of the macrophage.Sustained mitogen-activated protein kinase activation with Aggregatibacter actinomycetemcomitans causes inflammatory bone loss Mitogen-Activated Protein Kinase 2 Signaling Shapes Macrophage Plasticity in Aggregatibacter actinomycetemcomitans-Induced Bone Loss.Simvastatin inhibits lipopolysaccharide-induced osteoclastogenesis and reduces alveolar bone loss in experimental periodontal disease Alveolar bone loss: mechanisms, potential therapeutic targets, and interventions.JNK signaling plays an important role in the effects of TNF-α and IL-1β on in vitro osteoblastic differentiation of cultured human periosteal-derived cells.Aggregatibacter actinomycetemcomitans, a potent immunoregulator of the periodontal host defense system and alveolar bone homeostasis.The Role of Mitogen-Activated Protein Kinase-Activated Protein Kinases (MAPKAPKs) in Inflammation.Tristetraprolin regulates interleukin-6 expression through p38 MAPK-dependent affinity changes with mRNA 3' untranslated region.Peripheral blood mononuclear phagocytes from patients with chronic periodontitis are primed for osteoclast formation.Interference RNA in immune-mediated oral diseases - minireview.Dual action of highbush blueberry proanthocyanidins on Aggregatibacter actinomycetemcomitans and the host inflammatory response.A Chemically Modified Curcumin (CMC 2.24) Inhibits Nuclear Factor κB Activation and Inflammatory Bone Loss in Murine Models of LPS-Induced Experimental Periodontitis and Diabetes-Associated Natural Periodontitis.

P2860

Q33881772-9C780FF5-9952-4CDA-84D6-D2D78369F15B Q35577020-9B73DDF6-C688-4E0F-88E5-9EBFD60F170A Q35725536-74ADE298-D598-4486-97B1-D98CDDCCFD41 Q35963446-2C394ACD-C601-4B54-B3DB-3E61DA896CC3 Q36235672-89913168-F930-4048-BB0C-499AF2C1E6DF Q37546949-551F5428-5296-43A4-A54B-D41BCCC03C84 Q37691945-35CCB561-A9A4-4270-BBC1-1E50A1D5DB45 Q38204892-C971DAC4-A154-4BC2-A49A-929A8F05D404 Q38315680-030F3B68-6C10-428A-96BE-4C00425B5DFC Q38551613-5A469687-EB64-48BD-AC40-9A9DCB08A594 Q41887469-17833AFB-1E6F-46F1-9A90-9E1C01C58327 Q42279904-11032052-EB23-4454-B0DB-1EC5021483A4 Q45272768-336378FC-61BA-418C-A6C8-24BB99968408 Q47139740-19CD9B09-65FE-4852-B62A-D3D7AF207EBD Q49166585-14D53ED3-0ED5-4E77-967B-2C599DDE6864 Q52866845-F1B0E516-B1F4-4AEA-8D1A-ADCB09D8D527

P2860

Silencing mitogen-activated protein kinase-activated protein kinase-2 arrests inflammatory bone loss.

http://www.wikidata.org/entity/Q34702307

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Silencing mitogen-activated pr ...... rrests inflammatory bone loss.

@ast

Silencing mitogen-activated pr ...... rrests inflammatory bone loss.

@en

Silencing mitogen-activated pr ...... rrests inflammatory bone loss.

@nl

type

label

Silencing mitogen-activated pr ...... rrests inflammatory bone loss.

@ast

Silencing mitogen-activated pr ...... rrests inflammatory bone loss.

@en

Silencing mitogen-activated pr ...... rrests inflammatory bone loss.

@nl

prefLabel

Silencing mitogen-activated pr ...... rrests inflammatory bone loss.

@ast

Silencing mitogen-activated pr ...... rrests inflammatory bone loss.

@en

Silencing mitogen-activated pr ...... rrests inflammatory bone loss.

@nl

P1433

Q34702307-E7106B88-347A-4324-A583-1C1B0D5BB464

P1476

Q34702307-D560194F-D6B6-4842-B5BB-A98A02FEB6DA

P2093

Q34702307-00713A56-7A82-4D01-9F27-C34FA6464A2D

Q34702307-070DBD10-ED0A-452E-8FBB-BCDCFDD9C11C

Q34702307-137371B2-A0C8-45EC-810C-04A8B33E321A

Q34702307-3CEE5AEE-9643-413B-9E39-8C92D1552A18

Q34702307-83C2C48F-A2B7-4107-9657-FA7460748CB6

Q34702307-8E736959-27EC-47FF-89A6-A14A99B346CC

Q34702307-AB5BFC3B-F334-46F4-B75A-5D9209E7ECB5

Q34702307-D1804162-3304-4366-BC67-F37B64AE03E3

P2860

Q34702307-0381B969-A315-4FF9-AF61-378A6FC94639

Q34702307-0C087D49-40F6-4505-A0A4-8B3572B0C389

Q34702307-0F0642C7-1345-4306-A983-98C928ECF0A6

Q34702307-1B8BFE91-8A68-4BA0-9017-EC98130F9194

Q34702307-22362919-5227-4874-97A3-A716ACF73EB8

Q34702307-287CC5C1-D096-46DB-BF18-8E4F1424FFE1

Q34702307-3581D77D-74FC-488B-8BCE-86CBB56ACA94

Q34702307-4A59C6E9-2D2F-451B-AFCD-B76B57F39656

Q34702307-4E5E1BFA-D1BC-468F-85BA-694ADD92DC8E

Q34702307-57C8091D-6A4A-4F31-AF51-9A34A9FF29BA

P304

Q34702307-19D55AE9-7DEA-45DC-B757-BE9B00D838DF

P31

Q34702307-B2BF33D6-122F-4EFF-AE24-2FC39CE42FE4

P356

Q34702307-FA5D0E21-420B-453E-BA9A-65A23B018CE5

P407

Q34702307-B07A08B6-3304-4C60-AFBA-6A916E759F25

P433

Q34702307-2F61173D-15EB-48A7-A429-20A0122C3A64

P478

Q34702307-189EA699-B271-4BCF-9122-465FD8216AB8

P577

Q34702307-913066D2-7FB2-475C-A3F5-E1C23E67526A

P5875

Q34702307-EC311B05-7F84-4F86-9E4F-BC6CA357F000

P698

Q34702307-E1D01253-F784-445E-8446-8611E2F3E97E

P921

Q34702307-B3879EC7-F633-4672-A44A-7BF9C379DAC9

P932

Q34702307-837EF66C-EA4F-4175-ABAC-808BFB4F65A1

P356

JPET.110.172395

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Silencing mitogen-activated pr ...... rrests inflammatory bone loss.

@en

P2093

Angen Liu

http://www.w3.org/2001/XMLSchema#string

Bethany Herbert

http://www.w3.org/2001/XMLSchema#string

Carlos Rossa

http://www.w3.org/2001/XMLSchema#string

Hong Yu

http://www.w3.org/2001/XMLSchema#string

Keith L Kirkwood

http://www.w3.org/2001/XMLSchema#string

Kylie Martin

http://www.w3.org/2001/XMLSchema#string

Qiyan Li

http://www.w3.org/2001/XMLSchema#string

Robert Zinna

http://www.w3.org/2001/XMLSchema#string

P2860

MAP kinase activation in macrophages

MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding

Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin

MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels

MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis

KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model.

p38 MAPK regulates IL-1beta induced IL-6 expression through mRNA stability in osteoblasts

Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element

MAP kinase phosphatase-1 protects against inflammatory bone loss.

Actinobacillus actinomycetemcomitans lipopolysaccharide-mediated experimental bone loss model for aggressive periodontitis

P304

633-642

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.110.172395

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

336

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49665381

http://www.w3.org/2001/XMLSchema#string

P698

21139061

http://www.w3.org/2001/XMLSchema#string

P921

P932

3061533

http://www.w3.org/2001/XMLSchema#string